Advanced Neuromodulation Systems Reports First Quarter Results
Revenue Increases 21% DALLAS, April 28 /PRNewswire-FirstCall/ --
Advanced Neuromodulation Systems, Inc. (NASDAQ:ANSI) (ANS) today
announced operating results for the first quarter, provided a
review of its strategy and recent accomplishments, and updated
guidance for 2005. First Quarter Results For the three months ended
March 31, 2005, revenue increased 21.4% to a record $32,335,000
from $26,633,000 for the first quarter of 2004. Sales of neuro
products increased 18.5% to $28,717,000 for this year's first
quarter compared to $24,228,000 a year earlier, as sales of ANS'
Genesis(R) and GenesisXP(TM) implantable spinal cord stimulation
(SCS) systems for the treatment of chronic pain continued to
perform well in the marketplace. Gross margin was 74% for both
periods. Net income for the first quarter of 2005 was $58,568,000,
or $2.76 per diluted share. This compares to net income for the
first quarter of 2004 of $3,969,000, or $0.19 per diluted share.
Net income for this year's first quarter included a pre-tax gain of
$85,244,000 from the previously announced sale of Cyberonics common
stock acquired in August 2004. Excluding the effects of this gain
as reconciled in the attached table, earnings for this year's first
quarter were $0.22 per diluted share. At March 31, 2005, ANS had
total cash and marketable securities of approximately $181 million.
ANS has no debt. Board Increases Share Repurchase Authorization to
2,000,000 Shares To date, the company has repurchased 923,674
shares of its common stock under a 1,000,000-share repurchase
authorization. ANS announced today that the Board of Directors has
increased the repurchase authorization to a total of 2,000,000
shares. Repurchases may be made from time to time in open market or
privately negotiated transactions, subject to price and
availability, and financed out of working capital. "The Board of
Directors believes that ANS common stock is an attractive
investment, and repurchasing shares is a sound use of working
capital under the right circumstances," said President and CEO
Chris Chavez. Following its repurchases to date, ANS currently has
about 19.8 million issued and outstanding shares. Strategic Review
Chavez continued: "The interventional neuromodulation market now
exceeds one billion dollars, and promises to become a multi-billion
dollar, multi- indication modality in the years ahead. As described
in the cover story in the March 7, 2005 edition of Business Week,
as well as in recent feature stories in Time, the Wall Street
Journal, and in a week-long segment on the Today Show, the clinical
indications that neuromodulation can address are large,
under-served and under-penetrated. Now more than ever,
neuromodulation holds the promise to improve the quality of life
for millions of people who suffer from chronic pain and other
chronic diseases. With the increasing awareness of the benefits of
neuromodulation, we are increasingly excited about our mission to
develop ever-improving neuromodulation technologies to address an
expanding set of clinical indications. "As we announced last
quarter, we have decided to pursue new indications for our
technology more aggressively, by accelerating clinical studies,
regulatory approval efforts and product development. We are
leveraging our platform technologies into emerging clinical
applications that we believe will fuel strong organic growth for
years to come. In addition to planned pivotal studies to treat
migraine headaches, essential tremor and Parkinson's disease, we
are systematically incubating such promising new indications as
depression, pelvic pain, obesity, tinnitus, angina, ischemic pain
associated with peripheral vascular disease, and traumatic brain
injury. ANS also recently acquired exclusive intellectual property
rights to stimulate a specific target in the brain to treat
Obsessive Compulsive Disorder (OCD), and we hope to initiate a
pilot study to further evaluate safety and efficacy for this
indication." Received FDA Approval Of Its Second Rechargeable IPG
ANS recently received FDA approval to market and sell its second
rechargeable implantable pulse generator (IPG), the Eon(TM)
Neurostimulation System. This was ANS' second rechargeable system
to be approved by the FDA since December 2004. "With approval of
our new Eon system now in hand, we are manufacturing product to
support a limited launch in the second quarter and a full market
launch in the third quarter of 2005," Chavez said. "We believe that
ANS has the broadest, most advanced product offering in the
industry to address the diverse needs of interventional pain
physicians and their pain patients who suffer from chronic pain.
ANS offers a full array of spinal cord stimulation devices to meet
this demand, including two rechargeable IPGs, five conventionally
powered IPGs and radio-frequency powered stimulators. Additionally,
ANS' Axxess(R) neurostimulation leads, designed for superior
handling and precise placement, recently received a 2005 Medical
Design Excellence Award (MDEA). We firmly believe that each kind of
system has its place in the treatment armamentarium. With our
impressive list of generators and equally impressive list of leads
and programmers, ANS is uniquely positioned to address the broad
needs of the market at many different price points," Chavez added.
Received FDA Approval For Pivotal Study of Migraine Headache ANS
also has received approval from the FDA to expand its feasibility
study to a pivotal study of neurostimulation for the treatment of
migraine headache. The first implants are expected in the second
quarter. "We expect the results of this pivotal trial to support a
future PMA submission for chronic headache. With an estimated 2.2
million people in the U.S. who suffer from severe migraines, we
believe that this application has significant clinical potential,"
Chavez said. Received IDE to Investigate DBS System For Essential
Tremor ANS recently received an FDA Investigational Device
Exemption (IDE) approval to implant 160 patients at 12 sites to
investigate the safety and efficacy of the ANS Libra(TM) Deep Brain
Stimulation (DBS) System to treat essential tremor. The company has
identified a number of sites for the clinical study. The first
implants of the Libra DBS System to treat essential tremor are
anticipated to occur in the second quarter. Received IDE to
Investigate DBS System For Parkinson's Disease ANS also received
IDE approval from the FDA to implant 136 patients at 12 sites to
investigate the safety and efficacy of the ANS Libra DBS System to
treat Parkinson's disease. The company has identified a number of
sites for the clinical study. The first implants of the Libra DBS
System to treat Parkinson's disease are anticipated to occur in the
second quarter. "With these two approvals for essential tremor and
Parkinson's, we are moving into the deep brain stimulation arena,
which presents many new growth opportunities for our platform
technologies to address various neurological conditions," Chavez
said. "Estimates of the prevalence of these two conditions vary
significantly, but it is generally estimated that approximately 1.9
million people in the U.S. alone suffer from Parkinson's disease,
while approximately 5 million people in the U.S. suffer from
essential tremor. An independent market research firm estimates
that the market for DBS for these specific indications will grow to
approximately $180 million by 2008 and will continue to grow as
improvements in the procedure and stereotactic targeting are made."
Acquired Exclusive Rights For Method To Treat Depression Through
DBS ANS also recently announced that it has acquired exclusive
rights to intellectual property covering a unique method of
treating chronic treatment- resistant depression through DBS. The
highly-respected neuroscience journal Neuron recently reported
clinical results in a depression research study using this method
of deep brain neurostimulation. Authored by noted clinical
researchers including the inventors, the article reports "a
striking and sustained remission of depression in four of six
patients." Treatment-resistant depression, or TRD, is a severely
disabling disorder with very limited proven treatment options once
multiple medications, psychotherapy have failed and
electroconvulsive therapy has either been declined or failed. The
National Institutes of Health (NIH) estimate that 9.9 million adult
Americans suffer from major depressive disorder. Research indicates
that approximately 20% of these patients are resistant to existing
treatments. Approximately 100,000 people in the United States are
treated with electroconvulsive therapy (ECT) each year. "We caution
that these results cover only six patients, follow-up was limited,
and no sham surgery or systematic placebo control arm was used.
Despite these and other limitations in this research, the response
rate in these patients is striking given their extreme resistance
to other treatments and the well-documented low placebo response in
these patients. Based on the strength of this study, we are
pursuing a multi-center feasibility study to further evaluate
efficacy, and if the expanded study continues to impress, ANS
intends to pursue a pivotal trial for this important application,"
Chavez said. Management Updates Guidance for 2005 Chavez said that
management continues to expect revenue for 2005 of approximately
$145 million. With respect to the earnings outlook for 2005, the
CEO continued, "As previously announced, we have decided to
accelerate our pursuit of new indications for our technology more
aggressively, by accelerating clinical studies, regulatory approval
efforts and product development. While we will remain focused on
profitable bottom-line performance and growth in our core pain
business, we continue to expect to significantly increase our
investment in clinical studies, regulatory and R&D in 2005
compared to 2004. Including the impact of these increases, we
currently expect net income for 2005 in the range of $3.49 to $3.52
per diluted share." Conference Call ANS has scheduled a conference
call today at 11:00 a.m. EDT. The simultaneous webcast is available
at http://www.ans-medical.com/investors . A replay will be
available at this same Internet address, or at (800) 633-8284,
reservation #21244484, after 1:00 p.m. EDT. About Advanced
Neuromodulation Systems Advanced Neuromodulation Systems designs,
develops, manufactures and markets implantable systems used to
manage chronic intractable pain and other disorders of the central
nervous system. Fortune magazine recently ranked ANS as the 8th
fastest growing small company in its annual list of the Top 200
Fastest Growing Small Companies in the United States. Forbes
magazine recently recognized ANS as one of America's 200 Best Small
Companies. Frost & Sullivan, an international strategic market
research firm, also recently presented ANS with its Product
Innovation Award, recognizing ANS as the technology innovation
leader in the neurostimulation market and ANS' Genesis(R)
Implantable Pulse Generator system as the most advanced fully
implantable spinal cord stimulator on the market. Additional
information is available at http://www.ans-medical.com/ . "Safe
harbor" statement under the Private Securities Litigation Reform
Act of 1995: Statements contained in this document that are not
based on historical facts are "forward-looking statements." Terms
such as "plan," "should," "would," "anticipate," "believe,"
"intend," "estimate," "expect," "predict," "scheduled," "new
market," "potential market applications" and similar expressions
are intended to identify forward-looking statements. Such
statements are by nature subject to uncertainties and risks,
including but not limited to market acceptance of our new
rechargeable IPGs, as well as continued market acceptance of our
conventional IPGs and radio-frequency powered SCS systems;
competition from and the launch of new competitive products by
Medtronic, Advanced Bionics/Boston Scientific or others, as well as
other market factors that could impede growth in or reduce sales of
the Company's IPG and RF systems, which could adversely affect
revenues and profitability; patient or physician selection of less
invasive or less expensive alternatives; adverse changes in
coverage or reimbursement amounts by Medicare, Medicaid, private
insurers, managed care organizations or workers' comp programs;
intellectual property protection and potential infringement issues;
the cost, uncertainty and other risks inherent in litigation
generally, including without limitation the intellectual property
and patent litigation against Advanced Bionics; obtaining necessary
government approvals for other new products or applications and
maintaining compliance with FDA product and manufacturing
requirements; product liability; reliance on single suppliers for
certain components; completion of research and development projects
in an efficient and timely manner; successful patient enrollment in
and timely implementation of the IDE clinical studies for migraine
headache, Essential Tremor and Parkinson's disease; physician and
patient acceptance of the Libra DBS system for the Essential Tremor
and Parkinson's disease studies, for which already-approved
products are already available on the market; the uncertainty of
clinical results that may ensue from these clinical studies; the
risk that the FDA may not approve our PMA applications for these
applications following the completion of the clinical trials; the
satisfactory completion of feasibility, pilot and pivotal studies
and/or market tests prior to the introduction of new products
generally; successful integration of acquired businesses, products
and technologies; international trade risks; and other risks
detailed from time to time in the Company's SEC filings. In
addition, despite the encouraging results reported in the Neuron
article, there are limitations to this first study of DBS for TRD.
Sample size was small, follow-up was limited, and no sham surgery
or systematic placebo control arm was used. There were also
limitations on identifying markers that might predict response.
Differences in electrode targeting and placement may have also
contributed to the observed response variance. The mechanisms of
action of DBS are incompletely understood. These and other factions
require testing of additional subjects. Consequently, if such
management assumptions prove to be incorrect or such risks or
uncertainties materialize, anticipated results could differ
materially from those forecast in forward-looking statements. Such
forward-looking statements speak only as of the date on which they
are made, and the Company does not undertake any obligation to
update any forward-looking statement to reflect events or
circumstances after the date of this release. Advanced
Neuromodulation Systems, Inc. and Subsidiaries Condensed
Consolidated Statements of Income (Unaudited) Three Months Ended
March 31, 2005 2004 Net revenue $32,335,463 $26,632,863 Cost of
revenue 8,446,834 6,965,532 Gross profit 23,888,629 19,667,331
Operating expenses: Sales and marketing 10,090,319 8,564,046
Research and development 3,324,707 2,314,950 General and
administrative 3,343,454 2,316,740 Amortization of intangibles
639,980 574,874 17,398,460 13,770,610 Income from operations
6,490,169 5,896,721 Other income (expense): Gain on sale of
marketable securities 85,244,301 --- Foreign currency transaction
loss (47,625) (29,347) Investment income 546,861 251,329 85,743,537
221,982 Income before income taxes 92,233,706 6,118,703 Income
taxes 33,665,303 2,150,112 Net income $58,568,403 $3,968,591 Basic
income per share: Net income $2.88 $.20 Number of basic shares
20,366,990 19,928,946 Diluted income per share: Net income $2.76
$.19 Number of diluted shares 21,192,297 21,187,163 ADVANCED
NEUROMODULATION SYSTEMS, INC. and SUBSIDIARIES Condensed
Consolidated Balance Sheets (Unaudited) March 31, December 31, 2005
2004 Assets Current assets: Cash and marketable securities
$180,676,803 $124,016,064 Receivable, trade net 25,598,912
25,322,813 Receivable, interest and other 1,106,898 638,987
Inventories 24,754,210 23,923,851 Deferred income taxes 1,994,747
2,029,091 Prepaid expenses and other current assets 1,357,241
1,888,957 Total current assets 235,488,811 177,819,763 Net
property, equipment and fixtures 33,277,977 33,175,329 Minority
equity investments in preferred stock 1,104,000 1,104,000 Goodwill,
patents, tradenames, purchased technology & other assets, net
35,342,461 35,388,049 Total assets $305,213,249 $247,487,141
Liabilities and Stockholders' Equity Current liabilities: Accounts
payable $2,688,037 $3,206,516 Accrued salary and employee benefit
costs 1,933,556 2,390,721 Accrued commissions 1,579,853 2,656,112
Income taxes payable 33,526,811 708,412 Deferred revenue 107,028
165,861 Other accrued expenses 445,318 342,075 Total current
liabilities 40,280,603 9,469,697 Deferred income taxes 6,056,418
14,734,487 Non-current deferred revenue 670,362 718,820 Total
stockholders' equity 258,205,866 222,564,137 Total liabilities and
stockholders' equity $305,213,249 $247,487,141 Advanced
Neuromodulation Systems, Inc. and Subsidiaries Non-GAAP
Reconciliation (Unaudited) Three Months Ended March 31, 2005 Impact
of Cyberonics, Inc. Gain Income before income taxes $92,233,706
Gain on sale of Cyberonics, Inc. investment, net of acquisition
costs (85,244,301) Income before gain on sale of Cyberonics, Inc.
investment and income taxes 6,989,405 Income tax expense 33,665,303
Impact of gain on sale of Cyberonics investment (31,267,937) Income
tax expense before gain on sale of Cyberonics, Inc. 2,397,366 Net
income before gain on sale of Cyberonics, Inc. investment
$4,592,039 Number of diluted shares 21,192,297 Diluted income per
share $.22 Note: The Company believes that the Non-GAAP measurement
of net income before the gain on sale of Cyberonics, Inc.
investment assists investors in understanding the impact on the
Company's diluted earnings per share of the gain on sale of
Cyberonics, Inc. investment. The Company's effective tax rate of
36.5% was adjusted to 34.3% for purposes of the Non-GAAP
measurement above, which closely approximates the Company's 2004
effective tax rate of 34.4%. DATASOURCE: Advanced Neuromodulation
Systems, Inc. CONTACT: investors, Neil Berkman Associates,
+1-310-277-5162, or , for Advanced Neuromodulation Systems, Inc.;
or Chris Chavez, President & CEO of Advanced Neuromodulation
Systems, Inc., +1-972-309-8000 Web site:
http://www.ans-medical.com/ http://www.ans-medical.com/investors
Copyright
Advanced Neuromodulation (NASDAQ:ANSI)
Historical Stock Chart
From May 2024 to Jun 2024
Advanced Neuromodulation (NASDAQ:ANSI)
Historical Stock Chart
From Jun 2023 to Jun 2024